Even the stock share prices in Gilead Sciences, which is in the testing phase of a drug called Remdesivir to treat coronavirus is not responding upward the way analysts expect it would, likely from being slowed down by a lack of eligible recruits in China.

[Giliad and] Regeneron Pharmaceuticals are both making progress in developing treatments for coronavirus, according to a report published Monday by Leerink Research. But the stocks were off more than 4% in afternoon trading, a sign that investors remain skeptical.

Early indications are that Gilead’s (ticker: GILD) antiviral drug Remdesivir, originally developed to treat Ebola virus, is the most promising treatment for severe cases of coronavirus, analyst Geoffrey Porges writes.

Here's an article from February on how the testing was progressing